Corporate & Investor Presentation

Capital allocation $ in millions 2Q21 Capital Allocation Cash and cash equivalents $256 Debt $826 Higher priority Organic business growth Net debt $570 Free cash flow Free cash flow $135 Unused borrowing capacity $1,435 Dividends M&A NOTE: Values may not calculate due to rounding During 2Q21 $55M invested in R&D (7% of revenue) Paid $57M in dividends to shareholders 32 2021 ResMed | Corporate & Investor Presentation - updated 28JAN21 * Share buybacks* Share buyback program currently suspended Lower priority ResMed

View entire presentation